Qiming Venture Partners Ranks Top 5 in 2024 Global Biopharma VC Firms, Only Chinese Firm in Top Five
The ranking spotlights venture capital firms dedicated to life sciences, institutions that continue to drive the process of new drug R&D.
Recently, Endpoints News released its 2024 Global Top 100 Biotech Venture Capital Firms ranking based on data from DealForma. The list focuses on venture capital firms dedicated to the life sciences sector, institutions that continue to drive the drug development process forward.
Qiming Venture Partners ranked in the top 5 of the 2024 Global Top 100 Biotech Venture Capital Firms, and was the only Chinese venture capital firm in the top five.
Qiming Venture Partners
Ranked
2024 Global Top 5 Biotech Venture Capital Firm
Endpoints News found that venture capital funding has become increasingly concentrated in recent years, with investors showing greater appetite for biopharma sectors with innovative potential. Specifically, funding for biopharma/platform technology accounted for over 55% of total financing in both 2023 and 2024, higher than in 2021 and 2022. With $27.3 billion in funding, this sector became the primary destination for venture capital over the past year, followed by manufacturing and services.
Since 2022, the biopharma sector has shown a trend of fewer Series A rounds but larger individual deal sizes. Investors are devoting more resources and capital to earlier-stage projects to better position them for subsequent fundraising. At the same time, the sector overall has seen fewer financing rounds but larger amounts per round.
Among biopharma companies that raised funding last year, small molecule and antibody (excluding ADC) companies comprised the largest group, followed by AI. Looking specifically at early-stage investment (seed through Series A), venture capital firms focused primarily on leading drug modalities and therapeutic areas. Biologics, antibodies, DNA, and RNA were the most favored by investors, followed by small molecules and cell therapy. By therapeutic area, oncology remained the primary concentration of capital, followed by neurology, endocrinology, and autoimmune diseases.
Past Coverage
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming has focused on investing in outstanding early and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. More than 80 portfolio companies have become recognized unicorns or super-unicorns.
Many companies in Qiming's portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), APT Medical (688617.SH), New Horizon Health (06606.HK), Sanyou Medical (688085.SH), AmoyDx (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Caidya, Belief BioMed, Biren Technology, and others.